Cambridge, Massachusetts & Hangzhou, China, April 20, 2026

In a significant strategic move within the biopharmaceutical industry, Biogen Inc. has entered into a definitive agreement with TJ Biopharma to acquire exclusive rights to the investigational antibody felzartamab in the Greater China Region, thereby consolidating global ownership and commercialization rights under one entity. This transaction marks a major milestone in Biogen’s expansion strategy, reinforcing its commitment to advancing innovative therapies for immune-mediated diseases. The deal includes an upfront payment of $100 million and potential milestone payments reaching up to $850 million, alongside royalties on future sales, highlighting the commercial importance of this asset in a rapidly growing healthcare market.

Strategic Expansion in a High-Growth Market

The acquisition underscores Biogen’s focus on strengthening its footprint in Greater China, a region with one of the largest patient populations for conditions like IgA nephropathy (IgAN) and primary membranous nephropathy (PMN). These diseases represent significant unmet medical needs, with high progression rates to end-stage kidney disease (ESKD).

By securing full rights to felzartamab, Biogen gains complete control over development, manufacturing, and commercialization, enabling streamlined execution of its global strategy. The agreement also builds upon an existing collaboration between the two companies, particularly in Phase 3 clinical trials initiated in 2025. This move positions Biogen to leverage its global expertise while capitalizing on TJ Biopharma’s regional development success and infrastructure, including its GMP manufacturing facility in Hangzhou.

Felzartamab: A Promising Pipeline-in-a-Product

Advertisement

cGxPJobs Banner

Felzartamab is a CD38-directed monoclonal antibody designed to target plasma cells and modulate immune responses, offering potential applications across a wide spectrum of autoimmune and immunological disorders. Its mechanism of selectively depleting CD38+ plasma cells has shown promise in early clinical studies, suggesting improved outcomes in diseases driven by pathogenic antibodies.

Currently under evaluation in multiple global Phase 3 trials, including indications such as antibody-mediated rejection (AMR) in kidney transplants, IgAN, and PMN, felzartamab is being positioned as a first-in-class therapeutic candidate. Additionally, a Biologics License Application (BLA) for its use in multiple myeloma is under regulatory review in China, further expanding its potential clinical impact. Despite its promise, the therapy remains investigational, with safety and efficacy yet to be fully established by regulatory authorities.

Financial and Industry Implications

From a financial perspective, this transaction reflects the increasing value placed on late-stage biologics and immunotherapy assets in the global market. The structured deal—combining upfront payments, milestone incentives, and royalties—demonstrates a balanced risk-sharing model between the two companies. For TJ Biopharma, the agreement provides immediate capital infusion and long-term revenue participation, enabling continued investment in its next-generation antibody pipeline.

For Biogen, the acquisition enhances its pipeline diversification and strengthens its competitive position in the immunology segment, which is witnessing rapid innovation and market growth. Industry analysts view this deal as part of a broader trend where major biotech firms are consolidating rights to high-potential assets to accelerate global commercialization and regulatory alignment.

Overall, the Biogen–TJ Biopharma agreement represents a strategic consolidation of global rights, positioning felzartamab as a key asset in the future of immune-mediated disease treatment. With ongoing clinical trials and regulatory progress, the therapy could emerge as a transformative option in nephrology and beyond, reinforcing Biogen’s leadership in innovative biologics development.

Source: Biogen, TJ Biopharma press release